Mucopolysaccharide polysulphate

PreclinicalSmall molecule

Mucopolysaccharide polysulphate is one of 3 small molecule programs targeting Phlebitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PhlebitisActive, not recruiting

PhlebitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Phlebitis

#DrugCompanyPhaseTrials

Olux

HHarrow Inc

Phase 2

1 2

Nitrostat

VViatris Specialty LLC

Phase 1

1 3

Mucopolysaccharide polysulphate

TTan Tock Seng Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Phlebitis1 trial

Effectiveness of Topical Glycerine Sulphate Paste, Hirudoid Cream and Nil Application on Superficial Phlebitis

Completed·TTan Tock Seng Hospital·N/A·NCT01226069·147 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mucopolysaccharide polysulphate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mucopolysaccharide polysulphate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mucopolysaccharide polysulphate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tan Tock Seng Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTan Tock Seng Hospital

Mucopolysaccharide polysulphate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Phlebitis1 trial

References

Drug Info

Quick Facts

Related News